STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Perceptive Group Discloses 2.47M-Share Holding in Evolus (EOLS)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Perceptive Advisors LLC, its managing member Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. report beneficial ownership of 2,474,843 shares of Evolus, Inc. common stock, representing 3.8% of the outstanding class based on 64,685,419 shares outstanding as stated in the filing. The holdings are reported as shared voting and shared dispositive power; none of the Reporting Persons claim sole voting or sole dispositive power. The filing states the Master Fund directly holds the shares and Perceptive Advisors acts as its investment manager, with Mr. Edelman as managing member.

Positive

  • Full disclosure of ownership structure including manager, fund, and individual reporting persons
  • Clear numeric stake disclosed: 2,474,843 shares representing 3.8% of the class
  • Classification as shared voting and dispositive power removes ambiguity about control attribution

Negative

  • No sole voting or dispositive power—the Reporting Persons lack individual control over the shares

Insights

TL;DR A 3.8% disclosed stake by a specialized investment manager is material but non-controlling.

Perceptive's reported 2.47M shares equals 3.8% of Evolus based on the stated share count, positioning the group as a meaningful minority holder without sole voting authority. Shared voting and dispositive power indicate coordinated influence via the Master Fund and Perceptive Advisors rather than direct control. This level of ownership typically warrants monitoring for future changes in position, but by itself does not trigger control presumptions.

TL;DR Reporting shows clear disclosure of beneficial ownership with no indication of intent to seek control.

The Schedule 13G amendment correctly identifies the reporting persons and classifies the interest as shared voting/dispositive power. The certification asserts the holdings are not for the purpose of changing control, aligning with Schedule 13G treatment. Because there is no sole voting or dispositive power and ownership is under 5%, governance implications are limited unless future filings show accumulation or coordinated action with other holders.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Perceptive Advisors LLC
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:08/14/2025
Joseph Edelman
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman
Date:08/14/2025
Perceptive Life Sciences Master Fund, Ltd.
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:08/14/2025

FAQ

What stake does Perceptive Advisors report in Evolus (EOLS)?

Perceptive Advisors, Joseph Edelman, and Perceptive Life Sciences Master Fund report beneficial ownership of 2,474,843 shares, equal to 3.8% of the class.

Does Perceptive or Joseph Edelman have sole voting control of the reported EOLS shares?

No. The filing reports 0 sole voting power and 2,474,843 shared voting power for each Reporting Person.

Is the Perceptive stake in EOLS reported as intended to change control of the company?

No. The certification states the securities were not acquired and are not held for the purpose of changing or influencing control.

How was the 3.8% ownership percentage calculated in the filing?

The percentage is based on 64,685,419 shares outstanding as reported in the issuer's referenced quarterly report.

Which entity directly holds the reported Evolus shares?

The filing states the Master Fund directly holds 2,474,843 shares and Perceptive Advisors serves as its investment manager.
Evolus

NASDAQ:EOLS

EOLS Rankings

EOLS Latest News

EOLS Latest SEC Filings

EOLS Stock Data

447.90M
53.53M
11.81%
91.06%
17.98%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NEWPORT BEACH